These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38090966)

  • 21. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
    Urakawa H; Kawai A; Goto T; Hiraga H; Ozaki T; Tsuchiya H; Nakayama R; Naka N; Matsumoto Y; Kobayashi E; Okuma T; Kunisada T; Ando M; Ueda T; Nishida Y
    Cancer Sci; 2020 Sep; 111(9):3303-3312. PubMed ID: 32579783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
    Katz D; Azraq Y; Eleyan F; Gill S; Peretz T; Merimsky O
    BMC Cancer; 2016 Aug; 16():616. PubMed ID: 27501793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
    Sharma A; Kataria B; Biswas B; Bakhshi S; Pushpam D
    J Oncol Pharm Pract; 2022 Apr; 28(3):560-568. PubMed ID: 33719725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort.
    Karaağaç M; Sezgin Y; Eryılmaz MK; Araz M; Kaplan MA; Artaç M
    J Oncol Pharm Pract; 2020 Oct; 26(7):1657-1666. PubMed ID: 32063110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
    Kim HJ; Kim Y; Lee SJ; Lee J; Park SH
    J Gynecol Oncol; 2018 Jan; 29(1):e3. PubMed ID: 29185261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
    Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A
    J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
    Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM
    J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment.
    Takada K; Murase K; Nakamura H; Hayasaka N; Arihara Y; Iyama S; Ikeda H; Emori M; Sugita S; Nakamura K; Miyanishi K; Kobune M; Kato J
    Intern Med; 2019 Oct; 58(20):3009-3012. PubMed ID: 31243217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
    Munhoz RR; D'Angelo SP; Gounder MM; Keohan ML; Chi P; Carvajal RD; Singer S; Crago AM; Landa J; Healey JH; Qin LX; Hameed M; Ezeoke MO; Singh AS; Agulnik M; Chmielowski B; Luke JJ; Van Tine BA; Schwartz GK; Tap WD; Dickson MA
    Oncologist; 2015 Nov; 20(11):1245-6. PubMed ID: 26449382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
    Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
    J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
    Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
    Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis.
    Nakano K; Motoi N; Tomomatsu J; Gokita T; Ae K; Tanizawa T; Matsumoto S; Takahashi S
    BMC Cancer; 2016 Sep; 16(1):750. PubMed ID: 27663525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
    Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
    Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
    Gelderblom H; Judson IR; Benson C; Merimsky O; Grignani G; Katz D; Freivogel KW; Stein D; Jobanputra M; Mungul A; Manson SC; Sanfilippo R
    Acta Oncol; 2017 Dec; 56(12):1769-1775. PubMed ID: 28723233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series.
    Verschoor AJ; Gelderblom H
    Clin Sarcoma Res; 2014; 4():14. PubMed ID: 25302110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
    Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
    J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
    Bupathi M; Hays JL; Chen JL
    PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma　- A Single Institute Analysis.
    Wang X; Nakano K; Shiga T; Ohmoto A; Oyakawa T; Ebihara A; Sato Y; Fukuda N; Nishizawa M; Urasaki T; Ono M; Yunokawa M; Tomomatsu J; Takahashi S
    Circ J; 2024 Jan; 88(2):228-233. PubMed ID: 35314578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.